美国联邦医疗保险受益人停用地舒单抗后的后续骨质疏松治疗
该队列研究纳入2010至2021年启动地舒单抗(60 mg)的120,952例美国联邦医疗保险受益人,其中82,519例停药;仅6.0%在停药后1年内启动后续骨质疏松治疗,平均启动时间3.3个月;多数患者未启动后续治疗或重新使用地舒单抗。
要点
- 82,519例停用地舒单抗者中仅4912例(6.0%)在1年内启动后续骨质疏松治疗。
- 后续治疗最常见为阿仑膦酸钠3014例(3.7%)、唑来膦酸687例(0.8%)、伊班膦酸钠581例(0.7%)。
- 43.9%未启动后续治疗,41.3%在停药间隙后重新使用地舒单抗,8.8%失访。
核心结论
- 许多停用地舒单抗的患者未接受后续骨质疏松治疗。
- 作者认为主动随访和充分的临床沟通可减少治疗间隙并促进停药后启动后续治疗。
研究设计与样本
- 队列研究,从美国联邦医疗保险受益人20%随机样本中识别2010至2021年启动地舒单抗(60 mg)的患者,停药定义为用药间隔60天,随访至2022年。
- 共识别120,952例地舒单抗启动者,其中82,519例停药(平均年龄79.1岁[SD=7.2];90.3%女性)。
- 采用边际标准化多项逻辑回归估计风险比及95%置信限。
主要发现
- 82,519例停药者中仅4912例(6.0%)在停药后1年内启动后续治疗,从停药(末次索赔+243天)至后续治疗启动平均3.3个月(SD=3.4)。
- 后续治疗最常见为阿仑膦酸钠(n=3014;3.7%)、唑来膦酸(n=687;0.8%)、伊班膦酸钠(n=581;0.7%)。
- 43.9%未启动后续治疗,41.3%在停药间隙后重新使用地舒单抗,8.8%失访。
- 与较年长(≥85岁)相比,较年轻年龄、女性、既往骨质疏松治疗史、停药前仅有1-2次地舒单抗索赔(相对于更长疗程)是启动后续治疗(相对于未启动)的强预测因素。
关键数值与推荐
- 指南推荐在末次地舒单抗剂量后6个月内启动后续骨质疏松治疗。
- 本研究中后续治疗定义为停药后1年内使用口服或静脉双膦酸盐、特立帕肽和阿巴洛肽。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Denosumab is an effective osteoporosis therapy, but discontinuing treatment can result in rebound-associated fractures. Guidelines recommend starting follow-on osteoporosis therapy within 6 months of the last dose, but real-world practice is under-described. We found only 6.0% of patients initiated follow-on therapy within 1 year after denosumab discontinuation, suggesting many are at increased fracture risk. PURPOSE: We aimed to describe the incidence and predictors of follow-on osteoporosis therapy use for US Medicare beneficiaries who discontinued denosumab. METHODS: In this cohort study, we identified patients who initiated denosumab (60 mg) between 2010 and 2021 from a 20% random sample of Medicare beneficiaries. Denosumab discontinuation was defined as 60-day gap in use. During follow-up through 2022, we identified beneficiaries with follow-on osteoporosis therapy (i.e., oral and intravenous bisphosphonates, teriparatide, and abaloparatide) within 1 year after denosumab discontinuation. Multinomial logistic regression with marginal standardization was used to estimate risk ratios with 95% confidence limits for associations between covariates and follow-on therapy use after denosumab discontinuation. RESULTS: Of 120,952 denosumab initiators, we identified 82,519 individuals (mean age = 79.1 years [SD = 7.2]; 90.3% female) who discontinued denosumab. Only 4912 (6.0%) individuals initiated follow-on therapy after discontinuation; mean time from discontinuation (last claim + 243 days) to follow-on therapy initiation was 3.3 months [SD = 3.4]. Alendronate (n = 3014; 3.7%), zoledronic acid (n = 687; 0.8%), and ibandronate (n = 581; 0.7%) were most common. Most people did not initiate follow-on therapy (43.9%) or reinitiated denosumab after a gap (41.3%), with 8.8% lost to follow-up. Younger age (vs. ≥ 85 years), female sex, prior osteoporosis therapy, and Having 1-2 denosumab claims (vs. longer therapy) before discontinuation were strong predictors of follow-on therapy initiation versus no follow-on therapy. CONCLUSION: Many patients stopping denosumab do not receive follow-on therapy. Proactive follow-up and strong clinical communication would reduce treatment gaps and prompt follow-on therapy after discontinuation.
引用
- Sendhil SR, Cadarette SM, Aggarwal S, et al. Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries. Osteoporos Int. 2025. PMID: 41143882. doi:10.1007/s00198-025-07668-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。